| (CCTG) HN.9/LA-OSCC | Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC) | Meyers, Dr Brandon | Open to recruitment | NCT03410615 |
| (GSK) 209227 / INDUCE-4 | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Meyers, Dr Brandon | Open to recruitment | NCT04428333 |
| (JCC) SHINE / HNSBRT | A Phase 2 Study of SBRT for Squamous Cell Carcinoma of the Head and Neck | Lee, Dr Justin | Open to recruitment | NCT04435938 |
| (LHRI) RADIO/Cisplatin Hearing Loss/Cisplatin HD vs LD | Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity in the treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing curative concurrent chemoradiotherapy (RADIO) | Meyers, Dr Brandon | Open to recruitment | NCT03649048 |
| (GSK) 209229 / INDUCE-3 | A Randomized, Open-label, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Meyers, Dr Brandon | Suspended/On hold | NCT04128696 |
Find a Trial
Contact Us